Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database - Takeaways - MDSpire

Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database

  • By

  • Bo Cao

  • Mingfeng Shen

  • Chenchen Du

  • Qiuping Song

  • Zhongjie Ma

  • June 16, 2026

  • 0 min

Share

  • 1

    The study analyzed adverse events associated with neuraminidase inhibitors in pregnant women using the FDA Adverse Event Reporting System database.

  • 2

    A total of 3,687 adverse drug event reports were retrieved, with oseltamivir accounting for 3,211 reports and zanamivir for 471 reports.

  • 3

    Significant adverse events for oseltamivir included proctitis, infantile acne, congenital intestinal obstruction, and placental necrosis.

  • 4

    For zanamivir, notable adverse events included delivery complications, bronchospasm, and exposure during pregnancy.

  • 5

    The findings support the use of neuraminidase inhibitors as the primary antiviral treatment for pregnant women with influenza.

Original Source(s)

Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database

  • by Bo Cao, Mingfeng Shen, Chenchen Du, Qiuping Song, Zhongjie Ma

  • June 16, 2026

Related Content

Development and validation of a clinical prediction model for poor ovarian response in assisted reproductive technology

Serum vitamin D levels in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer